Search | Clinical Trials Finder

Conditions: Healthy Participants
Interventions: Metformin, Rilpivirine; Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Infection, Human Immunodeficiency Virus
Interventions: DTG 50 mg, RPV 25 mg, DTG/RPV 50 mg/25 mg: Product Code AS, DTG/RPV 50 mg/25 mg: Product Code AM, DTG/RPV 50 mg/25 mg: Product Code AQ, DTG/RPV 50 mg/25 mg: Product Code AK, DTG/RPV 50 mg/25 mg: Product Code AR; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: HIV-1
Interventions: Rilpivirine, Zidovudine, Abacavir, Tenofovir disoproxil fumarate, Lamivudine, Emtricitabine; Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: Syracuse, New York • Memphis, Tennessee

Conditions: HIV-1 Infection
Interventions: FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 57
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more

Conditions: HIV Infections
Interventions: DTG 50 mg, RPV 25 mg, CAR; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 13
States / cities: Bakersfield, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more

Conditions: HIV Infections
Interventions: Subjects do not receive study medication in this study 202094; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more

Conditions: HIV-1-infection, HIV Infections, HIV I Infection
Interventions: CAB + RPV; Drug
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 89 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: Oral Cabotegravir (CAB), Oral Rilpivirine (RPV), Long-Acting Injectable Cabotegravir (CAB LA), Long-Acting Injectable Rilpivirine (RPV LA), Combination Antiretroviral Therapy (cART); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 17 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 5 more

Conditions: Healthy
Interventions: Rilpivirine, Rilpivirine Long-acting Parenteral Formulation; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: HIV Positive
Interventions: darunavir/cobicistat, rilpivirine; Drug
Lead sponsor: Therapeutic Concepts; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), 2 NRTIs plus an INI, NNRTI, or PI; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 28 more

Conditions: HIV-DDI
Interventions: Riociguat (Adempas, BAY 63-2521), ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, Antiretroviral protease inhibitor; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Orlando, Florida • Boston, Massachusetts

Conditions: HIV-1 Infection
Interventions: FTC/RPV/TAF, EFV/FTC/TDF Placebo, EFV/FTC/TDF, FTC/RPV/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 79
States / cities: Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 57 more

Conditions: HIV-1-infection
Interventions: Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 40
States / cities: Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more

Conditions: HIV-1 Infection, HCV Infection
Interventions: E/C/F/TAF, F/R/TAF, LDV/SOF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: DTG, RPV, DTG/RPV FDC; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: HIV-1 Infection
Interventions: FTC/RPV/TDF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 18
States / cities: Long Beach, California • Los Angeles, California • San Diego, California + 12 more

Conditions: HIV-1 Infection
Interventions: F/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 34
States / cities: Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more

Conditions: HIV Infections
Interventions: DTG 50 mg, RPV 25 mg, CAR; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 13
States / cities: Long Beach, California • Los Angeles, California • San Francisco, California + 9 more

Conditions: HIV-1 Infection
Interventions: FTC/RPV/TAF, FTC/RPV/TDF Placebo, FTC/RPV/TDF, FTC/RPV/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 632 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 75
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 56 more

Conditions: HIV Infections
Interventions: Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 687 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 41
States / cities: Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more

Conditions: HIV-1 Infection
Interventions: Rilpivirine; Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 29
States / cities: Beverly Hills, California • Long Beach, California • Los Angeles, California + 26 more

Conditions: HIV, HIV Infections, Pregnancy
Interventions: Darunavir, Ritonavir, Etravirine, Rilpivirine, Darunavir/Cobicistat (FDC); Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 16
States / cities: Daytona Beach, Florida • Jacksonville, Florida • Miami, Florida + 13 more

Conditions: HIV Infections
Interventions: Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 1,049 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 33 more

Search by objective public record fields.

A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy Participants

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen

A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA

More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents

A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants

Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

Interaction With HIV Antiretroviral Agents

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)

Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1

A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults